Chimerix Announces Incentive Award for New Employee
Chimerix, a prominent biopharmaceutical company, has made a significant move to enhance its workforce by offering an inducement award to a new hire. On a recent date, the company’s Compensation Committee approved a grant of non-statutory stock options aimed to attract talent and promote long-term commitment. Specifically, the new employee has been granted options that allow the purchase of up to 130,000 shares of Chimerix’s common stock.
Understanding the Inducement Grant
The inducement award structure follows Nasdaq Listing Rule 5635(c)(4), designed to support recruitment strategies by providing attractive incentives for potential employees. The stock options are set at the closing trading price of Chimerix’s shares from the date of the grant, ensuring a fair and motivating entry point for the new employee.
Details of the Stock Options
These stock options come with a generous 10-year term and a vesting schedule spanning four years. The equity will partially vest after one year of employment, while the remaining options will vest in equal monthly installments over the next three years. Such a structure not only encourages retention but also aligns the interests of employees with those of shareholders.
Chimerix's Mission in Biopharmaceutical Development
Chimerix is not just focused on workforce enhancement but is equally devoted to its crucial mission of improving the lives of patients dealing with severe health challenges. The company is advancing notable clinical-stage development programs, particularly ONC201, which is being developed for H3 K27M-mutant glioma—a dire condition requiring innovative treatment solutions.
Current Clinical Programs
In addition to ONC201, Chimerix is actively conducting Phase 1 studies for ONC206, which aims to provide critical insights into safety and pharmacokinetics. This dedication to research signifies Chimerix’s commitment to discover medicines that yield meaningful health benefits for patients confronting life-threatening diseases.
Company Contacts
For those interested in more information or have inquiries regarding Chimerix’s operations or the recent stock options grant, please contact:
Will O’Connor
Stern Investor Relations
212-362-1200
Email: ir@chimerix.com
Email: will@sternir.com
Frequently Asked Questions
What type of stock options did Chimerix grant?
Chimerix granted non-statutory stock options to a new employee, allowing the purchase of 130,000 shares.
How long is the term for the stock options?
The stock options have a term of 10 years from the grant date.
What is the vesting schedule for the stock options?
The options vest over four years, starting with one-fourth vesting after the first year and the rest in equal monthly installments thereafter.
What is Chimerix's main mission?
Chimerix is focused on developing medicines that significantly improve and extend the lives of patients facing severe diseases.
What clinical programs is Chimerix currently pursuing?
Chimerix is advancing clinical programs for ONC201 and ONC206, which target serious conditions, including gliomas.
